 | Up a level |
Journal Article
Ansen, S., Schultheis, A., Hellmich, M., Leenders, F., Zander, T., Michels, S., Brockmann, M., Stoelben, E., Groen, H., Timens, W., Buettner, R., Thomas, R. K., Perner, S. and Wolf, J. (2014). PD-L1 expression and genotype in Non-Small Cell Lung Cancer (NSCLC). Oncol. Res. Treat., 37. S. 5 - 7. BASEL: KARGER. ISSN 2296-5262
Scheffler, M., Bos, M., Sos, M., Nogova, L., Gardizi, M., Mattonet, C., Papachristou, I., Kahraman, D., Kobe, C., Lammertsma, A., Boellaard, R., Persigehl, T., Heukamp, L., Buettner, R., Elter, T., Toepelt, K., Engel-Riedel, W., Stoelben, E., Neumaier, B., Dietlein, M., Zander, T. and Wolf, J. (2014). MIMEB: A phase II trial to evaluate FDG-PET/FLT-PET and DCE-MRI for early prediction of efficacy in patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab. Oncol. Res. Treat., 37. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262
Scheffler, M., Gardizi, M., Bos, M., Heukamp, L., Koenig, K., Serke, M., Nogova, L., Toepelt, K., Stoelben, E., Engel-Riedel, W., Randerath, W., Kaminsky, B., Panse, J., Zander, T., Buettner, R. and Wolf, J. (2014). Clinical and Molecular Characteristics of Non-Small Cell Lung Cancer Patients Harboring PIK3CA Mutations. Oncol. Res. Treat., 37. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262
Scheffler, M., Gardizi, M., Bos, M., Koenig, K., Michels, S., Fassunke, J., Heydt, C., Kuenstlinger, H., Ihle, M. A., Ueckeroth, F., Albus, K., Serke, M., Gerigk, U., Schulte, W., Toepelt, K., Nogova, L., Zander, T., Engel-Riedel, W., Stoelben, E., Ko, Y. -D., Randerath, W. J., Kaminsky, B., Panse, J., Becker, C., Hellmich, M., Merkelbach-Bruse, S., Buettner, R., Heukamp, L. C. and Wolf, J. (2014). Genetic heterogeneity and lack of prognostic impact of patients with non-small cell lung cancer (NSCLC) harboring PIK3CA mutation. Oncol. Res. Treat., 37. S. 65 - 66. BASEL: KARGER. ISSN 2296-5262
Stoelben, E., Huber, R. M., Mueller, R. -P. and Wolf, J. (2010). Multimodality therapy for lung cancer. Internist, 51 (11). S. 1348 - 1355. NEW YORK: SPRINGER. ISSN 0020-9554
Temming, S., Kocher, M., Semrau, R. and Stoelben, E. (2015). Outcome and Toxicity of CyberKnife Stereotactic Body Radiation Therapy for Inoperable Patients With NSCLC. Int. J. Radiat. Oncol. Biol. Phys., 93 (3). S. E400 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-355X
Temming, S., Kocher, M., Semrau, R., Stoelben, E. and Marnitz-Schulze, S. (2017). Robot-assisted stereotactic Radiotherapy in Patients with metachronous secondary Tumors in non-small cell Lung Cancer (NSCLC) Oncologic Findings and Toxicity. Strahlenther. Onkol., 193. S. S77 - 1. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-099X
Temming, S., Kocher, M. and Stoelben, E. (2016). Outcome and toxicity of stereotactic body radiotherapy with Cyberknife of inoperable patients with NSCLC. Oncol. Res. Treat., 39. S. 35 - 36. BASEL: KARGER. ISSN 2296-5262
Temming, S., Stoelben, E., Semrau, R. and Kocher, M. (2014). CyberKnife Radiosurgery for lung tumors: Report of clinical response and toxicity. Oncol. Res. Treat., 37. S. 87 - 88. BASEL: KARGER. ISSN 2296-5262